Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
20% albumin infusion for prevention of acute kidney injury after high-risk cardiac surgery
ACTRN12619001355167Phase 4Completed
- Sponsor
- Monash Health
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of albumin (human) in acute kidney failure (AKF) (2 arms), sponsored by Monash Health. Primary endpoint: Incidence of any stage acute kidney injury. Started Jul 2019; status: completed.
02
Drugs
albumin (human)
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ACTRN12619001355167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001355167.